French pharma major Sanofi (Euronext: SAN) might have threatened to play hardball over its attempt to take over USA-based biotech Medivation (Nasdaq: MDVN), but the target company has hit back.
Sanofi’s latest letter to Medivation, reiterating its desire to go ahead with the $9.3 billion takeover and warning it would resort to a hostile takeover if necessary, has prompted a stern response.
Medivation, which has a leading oncology franchise, is seen as a hot property by big pharma, with US major Pfizer (NYSE: PFE) and Anglo-Swedish AstraZeneca (LSE: AZN) also reportedly interested.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze